Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.

Vivek Subbiah,Tina Cascone,Kenneth R. Hess,Ishwaria Mohan Subbiah,Sarah Nelson,Naoto Morikawa,Monique B. Nilsson,Tarak Bhatt,Siraj M. Ali,William Nassib William,Victoria M. Raymond,Richard B. Lanman,David P. Carbone,Ravi Salgia,Taofeek K. Owonikoko,George R. Simon,Funda Meric-Bernstam,Robert C. Doebele,John Victor Heymach

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.

2018

Vivek Subbiah
Tina Cascone
Kenneth R. Hess
Ishwaria Mohan Subbiah
Sarah Nelson
Naoto Morikawa
Monique B. Nilsson
Tarak Bhatt
Siraj M. Ali
William Nassib William
Victoria M. Raymond
Richard B. Lanman
David P. Carbone
Ravi Salgia
Taofeek K. Owonikoko
George R. Simon
Funda Meric-Bernstam
Robert C. Doebele
John Victor Heymach

9035Background: RET fusions (RET+) occur in 1-2% of NSCLCs. Tumors eventually become refractory to multi-kinase RET inhibitor monotherapy. We evaluated the pre-clinical and clinical activity of the...

Keywords:

Cell
Discovery and development of mTOR inhibitors
Pathology
Lung cancer
Everolimus
Vandetanib
Medicine
Cancer research
Kinase
Refractory
in patient
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations